Taxorest
Bronchial bioregulator
Taxorest is a bronchial peptide complex. It is the only compound in this cohort whose target organ has a cheap, standardized, quantitative function test that is not a blood draw — spirometry — and the fact that nobody has published one for it is the most informative thing on this page. It also has a defined-peptide twin in this same catalog, which turns the class hypothesis into an experiment somebody could actually run.
Taxorest quick facts
| Reported research dose (Injectable) | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~15-30 min |
| Forms | Injectable, Oral |
| Evidence level | Russian studies; limited |
| Other forms available | Oral — dosed differently |
Respiratory cytogen — course-based lung support. Respiratory-directed, overlapping with the two above. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, peak flow before and after a course. Run it as an experiment you measure, not a protocol you trust.
What Taxorest actually is — and why that changes the mechanism
Taxorest is a bronchial and tracheal peptide complex. The most useful fact about it is one the vendor page mentions in passing and then drops: it is paired with Chonluten, and Chonluten is Glu-Asp-Gly, a defined tripeptide sold on this same site. So the respiratory tissue has both an extract and a synthetic peptide claiming it, from the same school, at the same time.
That pairing is a hypothesis with an experiment attached, and it is the same shape as the strongest argument in this class. Thymalin is a thymus extract whose originating group states in print that its action is due to the short peptides KE, EW and EDP in its composition — two of which are sold separately here as Vilon and Thymogen. Apply the same logic to the airway: either Taxorest works because it contains Glu-Asp-Gly, in which case the tripeptide is the cleaner product and the extract is a less verifiable way of buying it, or it works through something the tripeptide does not contain, in which case no synthetic in this catalog substitutes for it. Those are opposite buying decisions. One head-to-head study would separate them and nobody has run it.
What the extract itself commits to, which is very little. 'Peptide complex' names a process, not a composition. Chonluten's identity is three residues that can be written down, weighed and confirmed; Taxorest's identity is whatever the extraction produced on the day. The gene-regulation review from the originating group is organized by peptide sequence for exactly that reason — AEDG credited with 98 genes, KE with 36 — and a complex cannot appear in a table indexed by sequence.
And the route question is sharper here than anywhere else in the cohort. The airway epithelium is the one target tissue in this catalog that can be dosed directly, by nebulizer, without asking anything of the gut wall or the bloodstream. Inhaled delivery is ordinary medicine and the equipment costs less than a course of this. It is not how this product is sold, and the reason it is not is not stated anywhere.
What the primary literature on Taxorest actually says
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The gene-regulation review from the originating group. It is the source of the mechanism claim for the whole class — short peptides entering the nucleus and altering transcription — and it is worth reading for how it is organized: by PEPTIDE, with named sequences and named genes. AEDG is credited with 98 genes, KE with 36. There is no entry for a bronchial or tracheal complex, because a complex has no sequence to index.
Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
The 266-subject elderly series, cited here for its scope rather than its result. It used thymus and pineal preparations by injection. No respiratory endpoint was reported, no respiratory tissue was targeted, and spirometry does not appear in it. When a vendor page cites 'decades of Russian clinical work' behind a lung product, this is the study they mean, and it is not about the lung.
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
The independent systematic review — 24 randomized trials, 2,245 participants — included for calibration. Its endpoints were cognitive. It is the only outside grading this class has, and it found certainty of evidence low to very low across everything it could pool.
What is not here. Nothing is indexed under the trade name Taxorest. No spirometry result has been published for it, which is notable because spirometry is cheap, standardized and the obvious endpoint. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Taxorest evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Taxorest. The problem specific to Taxorest is that the test it would fail or pass is easy and free of the confounders that plague the rest of this catalog. Spirometry gives a number in liters, in ten minutes, in any clinic, and the technique is standardized to the point that the two best efforts of a session are required to agree closely before the result is accepted at all. A product sold for respiratory-tract function that has never been put through it is not short of evidence because evidence is expensive here. It is short of evidence because nobody looked.
The count, first, because it is the finding: 0. Zero trials, zero animal studies, zero mechanism papers under the name Taxorest, searched to 2 September 2026. Zero published spirometry results — not a negative result, not an underpowered one, none. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026 under the trade name and the tissue name.
Why the zero is louder here than on the other pages in this cohort. Most compounds in this class are aimed at endpoints that are genuinely expensive to measure — renal functional reserve, cartilage volume, ovarian reserve. Airway function is not one of them. Spirometry is cheap, standardized to the point that a session's 2 best efforts must agree closely before the result is accepted, available in any clinic, and it returns a number in liters in about 10 minutes. The absence of evidence here cannot be explained by the cost of the evidence: 0 trials is not what an expensive endpoint looks like.
What the references are actually supporting. Nothing about this product. The 266-subject elderly series used thymus and pineal preparations by injection and reported no respiratory endpoint. The independent review graded 24 randomized trials in 2,245 participants on cognitive endpoints and found certainty of evidence low to very low. The gene-expression review indexes by sequence and has no entry for a bronchial complex. Three real papers, none of them about the lung, all cited on vendor pages for this compound as though they were.
What is actually measured, and what is not. Measured: nothing. Not measured, and this is the list that matters because every item on it is cheap: spirometry before and after a course; the composition of the complex; whether Glu-Asp-Gly, the tripeptide the vendor pairs it with, is present in the extract at all; plasma half-life; oral bioavailability. The independent review that graded this class pooled 24 randomized trials in 2,245 participants and 0 of them had a respiratory endpoint.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Taxorest pharmacokinetics — how much of it actually gets in
Why the half-life field is empty and what belongs there instead. A mixture has one clearance curve per component, so the single figure the quick facts want does not exist for this preparation and has never been measured for it in any species. What can be said is that any short peptide in it meets serum aminopeptidases and proteases and is cut from its termini within minutes of reaching plasma.
Why that does not by itself sink the claim. The proposed mechanism is transcriptional. A signal that changes gene expression does not have to still be in the blood when the effect appears, which is why measuring the drug in serum would tell you nothing useful even if somebody did it. The measurement that matters is the airway's function, not the molecule's concentration.
The route arithmetic, and the specific reason it is odd here. Swallowed, a peptide meets gastric acid, pancreatic proteases and then the brush border of the small intestine, where the transporter the class relies on — PEPT1 — carries di- and tripeptides and not complexes. Anything absorbed then passes through hepatic first-pass extraction before reaching an artery. Oral bioavailability has never been published for this product or any product in this family. An injection skips all of it and is 100% bioavailable by definition. And an inhaled dose would skip both, landing on the target epithelium directly — the obvious route for a respiratory product, and the one route it is not sold in.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Taxorest to work
What would have to be true, and where the chain stops. (1) The complex would have to contain active short peptides — never published. (2) They would have to survive the chosen route and reach airway tissue — never measured; the route that would make this trivial, inhalation, is not offered. (3) They would have to enter epithelial cells and alter transcription — never observed in respiratory tissue for anything in this class. (4) That change would have to produce a measurable functional difference — the test exists, costs almost nothing, and has never been run.
Two of the predictions below are blood markers because those are the tests this site can link you to. The honest primary endpoint for this compound is not on this list at all: it is spirometry, before and after, and a reader who runs a course without it has chosen not to find out.
- Prediction 1 — hs-CRP (High-Sensitivity C-Reactive Protein). should fall if an airway-inflammation claim is doing any work, 3 months, which is the retest interval this site already uses for it. hs-CRP bands at under 1.0 mg/L for low risk, 1.0-3.0 average and above 3.0 high. It is not lung-specific, and that is exactly why it is the honest first test: if a systemic inflammatory marker does not move, the claim has to be about something local, and then it has to say what.
- Prediction 2 — Complete Blood Count (CBC) with Differential. the eosinophil count on the differential should be read before and after, before, and at 3 months. Eosinophils are the differential's airway line. In anyone whose respiratory symptoms are allergic or asthmatic, the eosinophil count is the cell that tracks it, and it comes free with a CBC nobody has to order specially.
- Prediction 3 — ESR (Sed Rate). should be flat; 0-15 mm/hr is the reference band and it moves slowly, 3 months. ESR is deliberately the slow marker. Pairing it with hs-CRP is how you tell a real change in inflammatory state from a single bad morning: CRP moves in days, ESR over weeks, and a claim that only shows up in the fast marker is a claim about the week you were tested.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Taxorest did to it — and that difference is the entire point of testing.
Taxorest versus the alternatives
Taxorest versus Chonluten is the comparison this page exists to force. Chonluten is Glu-Asp-Gly — three residues, one mass, confirmable by mass spectrometry, and a molecule the originating group's own literature can index. Taxorest is a preparation whose contents nobody has published. On verifiability the tripeptide wins outright. On clinical evidence both are at 0, which is worth saying twice, because 'better characterized' and 'better evidenced' are different properties and this market routinely sells the first as the second.
And against real respiratory medicine, which is where honesty costs something. If there is diagnosed airway disease, inhaled bronchodilators and corticosteroids have trial evidence measured in tens of thousands of participants and an endpoint that is the same cheap spirometry this product has never been through. If there is no diagnosed disease, the single largest determinant of lung function over a lifetime is not a peptide and never has been: it is whether you smoke. A product with 0 published respiratory results is not in the same conversation, and the reason this category is distrusted is that its pages do not say so.
What you are actually buying when you buy Taxorest
An extract has no identity test. A certificate of analysis on this product can establish sterility, endotoxin, total protein and the absence of named contaminants; it cannot confirm what the vial holds, because there is no structure to confirm it against and no mass to check, the way there is for a 3-residue synthetic. That is not an allegation about a vendor. It is what an extract is.
The specific test to ask for here, and it is unusual. Because this product has a defined-peptide twin, there is one analysis that would be genuinely informative: look for Glu-Asp-Gly in the extract. If the vendor's own pairing claim is right, the tripeptide should be present and quantifiable by mass spectrometry against a computed mass, and a number for it would be the first compositional fact ever published about this preparation in 0 papers to date. If it is absent, the pairing story is marketing. 0 vendors in this market have published that assay, and it would be one of the cheapest informative experiments in the entire catalog.
The capsules and the injection are sold as the same preparation, which is a strong claim and an unverifiable one — the two are different manufacturing streams and there is no assay that establishes an extract's identity in either. Ask for sterility and endotoxin on the injectable. Nothing on the oral certificate speaks to whether anything crosses the gut wall.
Where to get Taxorest
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Taxorest
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- The extract counterpart in the respiratory arm, conventionally paired with Chonluten in the Russian protocols. Practical record is thin and entirely self-reported outside Russia.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A tracheal/bronchial peptide complex proposed to support respiratory epithelium regeneration.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- The 'pair the extract with the peptide' convention has no published rationale — it is a protocol habit rather than a demonstrated synergy, and it is worth knowing that before buying two products instead of one.
What that tier rests on here. The tier above is class inference. Nothing is indexed under the trade name Taxorest, and the absence is unusually informative because the obvious endpoint for a respiratory product is spirometry — cheap, standardized, ten minutes, and never run on it.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
The bronchial evidence in this family belongs to a defined tetrapeptide, not to an extract. Kuzubova 2015 reports a modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium — a real tissue-level result in the right organ. Monaselidze 2011 is stranger and more informative: microcalorimetry of DNA in the presence of the bronchial peptide Ala-Asp-Glu-Leu, measuring a shift in melting temperature. Both concern Bronchogen, a synthetic four-residue molecule with a mass, a formula and a certificate that means something.
Taxorest is the extract of the same tissue with none of that. A PubTator3 search on 6 September 2026 returned no indexed record under this trade name in any language. Bronchial tissue is also absent from Ryzhak 2015, the seven-tissue organotypic survey, so there is not even an explant result to point at.
Which makes the transfer worth naming explicitly. A vendor citing bronchial-epithelium data for a bronchial extract is citing a different molecule. The two share a tissue of origin and a manufacturer. They do not share a composition, a mass, a route or a dataset, and no published work has compared them.
Where it stops. No spirometry, no exacerbation count, no symptom score, no imaging, for this product in any species. Khavinson 2021 reviews the gene-expression claim across the family and does not reach a lung.
What nobody has tested yet
Spirometry is the cheapest hard endpoint in respiratory medicine. FEV1 and FVC are objective, reproducible within a few percent, take ten minutes, and are the primary endpoint of essentially every airways trial ever run. A bronchial product with no published FEV1 value has never been tested against the number its own field uses to decide whether anything works.
Fractional exhaled nitric oxide would test the mechanism rather than the symptom. FeNO tracks eosinophilic airway inflammation, the machine sits in many clinics, and the measurement takes under a minute. If a bronchial peptide modulates airway inflammation, this is where it would show first — and nobody has looked.
Extrapolation, labeled as such. The lung is the one organ that can be dosed directly without solving the absorption problem at all. A nebulized or inhaled peptide reaches bronchial epithelium at concentrations an oral capsule could never produce, which is why inhaled therapy dominates airway medicine. If this class has a route worth developing, that is it — and in decades of availability, no inhaled formulation of any bioregulator has been published or tested.
Sources read for this page
- Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bulletin of Experimental Biology and Medicine 2015;159(5):685–688 · PMID 26468022
- Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine 2011;150(3):375–377 · PMID 21240358
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
Taxorest — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Taxorest — safety specifics for this compound
Specific to Taxorest: the risk that is real here is diagnostic delay, and respiratory symptoms are the category where that costs the most. Breathlessness, a cough that does not clear and wheeze all have causes that are diagnosable and several of them are treatable on a clock — asthma, chronic obstructive disease, heart failure, infection, and malignancy. The test that sorts most of them is spirometry, it takes about ten minutes, and this product has 0 published results on it. Using an unstudied capsule or vial to manage a symptom that has never been characterized is the specific failure mode. The class safety profile above is otherwise the right read: the tolerability record for organ peptide preparations is strikingly clean, and it comes almost entirely from one school. Nothing in the literature reports harm from this compound, because nothing in the literature reports anything about it.
Taxorest — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Taxorest moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
Taxorest — what interferes with this one specifically
What actually interferes here is the measurement, and specifically the timing of it. The two blood markers a reader is most likely to run alongside this — hs-CRP, banded at under 1.0 mg/L for low risk, 1.0-3.0 average and above 3.0 high, and ESR at 0-15 mm/hr — are non-specific acute-phase markers. Any intercurrent infection moves both, and a respiratory infection is the exact event most likely to happen during a course taken for respiratory reasons. A single post-course hs-CRP after a cold reads as the product having caused inflammation; a single one after recovering from that cold reads as the product having resolved it. Neither is true. The mitigation is a baseline pair, a repeat at 3 months, and a note of any illness in between. Second: inhaled corticosteroids, if prescribed, lower airway inflammatory markers on their own, so a course run alongside a recent inhaler change has two variables and 0 published data on one of them.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Taxorest in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Taxorest
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Taxorest — frequently asked questions
Is Taxorest a peptide or an extract?
An extract — a peptide complex from bronchial and tracheal mucosa, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Taxorest?
Nothing is indexed under the trade name Taxorest. No spirometry result has been published for it, which is notable because spirometry is cheap, standardized and the obvious endpoint.
What should I measure if I run Taxorest?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson VKh, Morozov VG — Peptides of pineal gland and thymus prolong human life · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
What Taxorest is used for
Taxorest appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.